

# Massimo Primignani

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7941474/massimo-primignani-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57  
papers

3,897  
citations

26  
h-index

62  
g-index

62  
ext. papers

4,555  
ext. citations

5  
avg, IF

4.92  
L-index

#	Paper	IF	Citations
57	Antithrombotic Therapy and Liver Disease <b>2022</b> , 249-265		
56	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	11
55	Association of portal venous system thrombosis with endoscopic variceal treatment: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 32, 125-131	2.2	2
54	Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> ,	2.2	4
53	High-dose pre-endoscopic intravenous proton pump inhibitors in upper gastrointestinal bleeding: Utility or futility?. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 387-388	3.3	1
52	Post-banding ulcer bleeding in the elective setting: Are there any risk factors?. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 658-660	3.3	
51	Clonal Megakaryocyte Dysplasia with Normal Blood Values Is a Distinct Myeloproliferative Neoplasm. <i>Acta Haematologica</i> , <b>2021</b> , 1-8	2.7	1
50	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1355-1366	13.4	2
49	Combined approach for embolization of otherwise unmanageable gastric varices. <i>Annals of Gastroenterology</i> , <b>2021</b> , 34, 510-515	2.2	
48	Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal EBlocker Therapy. <i>American Journal of Gastroenterology</i> , <b>2021</b> , 116, 1342-1344	0.7	3
47	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 342-350	13.4	10
46	Implementing pre-procedural thrombopoietin receptor agonists in cirrhotic patients with severe thrombocytopenia: Indiscriminate, selective or unneeded?. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1394-1395	3.3	0
45	Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00409	4.2	1
44	Letter to the Editor: Thromboelastography-Guided Blood Product Transfusion in Cirrhosis With Coagulopathy: Real Saving or Just Less Waste?. <i>Hepatology</i> , <b>2020</b> , 72, 1158-1159	11.2	0
43	Nonselective EBlockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study. <i>Advances in Therapy</i> , <b>2020</b> , 37, 1452-1463	4.1	8
42	ABO, von Willebrand factor/factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit?. <i>Liver International</i> , <b>2020</b> , 40, 1788-1789	7.9	1
41	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1082-1091	13.4	52

40	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , <b>2020</b> , 95, 156-166	7.1	27
39	Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. <i>Hepatology</i> , <b>2020</b> , 71, 658-669	11.2	40
38	Etiology of non-cirrhotic portal vein thrombosis in children: Few or many causes?. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 118-120	3.3	
37	Plasma miRNA-based signatures in CRC screening programs. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 1164-1173	7.5	21
36	Assessing spleen stiffness by point shear-wave elastography: Is it feasible and reproducible in patients with chronic liver disease? Is it useful to predict portal hypertension?. <i>GastroHep</i> , <b>2019</b> , 1, 205-213	13	1
35	Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1135-1140	3.3	16
34	Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 52-60	5.1	5
33	Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , <b>2019</b> , 69, 282-293	11.2	73
32	Incidence and mortality of renal dysfunction in cirrhotic patients with acute gastrointestinal bleeding: a systematic review and meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 1181-1188	4.2	7
31	Reply. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 798-799	6.9	
30	Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1146-1152.e4	6.9	46
29	Changing Concepts of Cirrhotic Coagulopathy. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 274-281	10.7	110
28	Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. <i>Liver International</i> , <b>2017</b> , 37, 694-699	7.9	128
27	Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis. <i>Liver International</i> , <b>2016</b> , 36, 1322-30	7.9	36
26	Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>United European Gastroenterology Journal</i> , <b>2016</b> , 4, 363-70	5.3	7
25	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 455-467	3.3	41
24	Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1208-13	13	18
23	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1118-25	13.4	56

22	Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. <i>Leukemia Research</i> , <b>2015</b> , 39, 525-9	2.7	10
21	Diagnosis of thrombophilia/prothrombotic conditions in patients with liver disease. <i>Clinical Liver Disease</i> , <b>2014</b> , 3, 126-128	2.2	3
20	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 148-54	13.4	113
19	Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 152-6	3.3	26
18	Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. <i>Journal of Hepatology</i> , <b>2013</b> , 59, 265-70	13.4	113
17	Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. <i>Liver International</i> , <b>2013</b> , 33, 362-7	7.9	84
16	Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. <i>Internal and Emergency Medicine</i> , <b>2012</b> , 7, 139-44	3.7	73
15	Portal vein thrombosis, revisited. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 163-70	3.3	97
14	Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. <i>Hepatology</i> , <b>2010</b> , 51, 210-8	11.2	342
13	Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. <i>Hepatology</i> , <b>2010</b> , 52, 249-55	11.2	103
12	High levels of factor VIII and risk of extra-hepatic portal vein obstruction. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 916-22	13.4	62
11	Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 288-95	13.4	25
10	An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. <i>Gastroenterology</i> , <b>2009</b> , 137, 2105-11	13.3	385
9	Etiology, management, and outcome of the Budd-Chiari syndrome. <i>Annals of Internal Medicine</i> , <b>2009</b> , 151, 167-75	8	329
8	The role of thrombophilia in splanchnic vein thrombosis. <i>Seminars in Liver Disease</i> , <b>2008</b> , 28, 293-301	7.3	42
7	MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. <i>Blood</i> , <b>2008</b> , 111, 4418	2.2	24
6	Reply:. <i>Hepatology</i> , <b>2007</b> , 45, 832-833	11.2	1
5	The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. <i>Hepatology</i> , <b>2007</b> , 46, 520-7	11.2	158

- 4 Thrombin generation in patients with cirrhosis: the role of platelets. *Hepatology*, **2006**, 44, 440-5 11.2 289
- 3 Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. *Hepatology*, **2006**, 44, 1528-34 11.2 220
- 2 Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. *Hepatology*, **2005**, 41, 553-8 11.2 506
- 1 Risk factors for thrombophilia in extrahepatic portal vein obstruction. *Hepatology*, **2005**, 41, 603-8 11.2 162